Genetic Testing Market revenue to reach USD 45 Billion by 2035, says Research Nester
16 janv. 2024 06h30 HE
|
Research Nester
New York , Jan. 16, 2024 (GLOBE NEWSWIRE) -- The global genetic testing market size is slated to expand at 9% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 45 billion...
Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
28 nov. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain | DelveInsight DelveInsight’s thalassemia...
Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR
25 août 2022 08h33 HE
|
Allied Market Research
Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
Blood Temperature Indicator Market Worth $504.37 Mn, Globally, by 2028 at 12.9% CAGR - Exclusive Report by The Insight Partners
18 mai 2022 08h58 HE
|
The Insight Partners
New York, May 18, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Blood Temperature Indicator Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
08 mars 2022 07h00 HE
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
26 mars 2009 12h54 HE
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that
it has received two orphan medicinal product designations from the European
Commission for its product...
HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug
09 déc. 2008 12h01 HE
|
HemaQuest Pharmaceuticals
SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced
today the successful completion of Phase 1 clinical trials of HQK-1001, an
orally-administered therapeutic...